Cargando…
Xiaoqinglong decoction suppresses childhood cough variant asthma and inhibited the body inflammatory response by regulating IL-6/STAT3 signalling pathway
Xiaoqinglong decoction (XQLD) is widely used clinically in the treatment of childhood cough variant asthma (CVA). However, its potential mechanism is still unknown. In the present study, the authors investigate the biological network and signalling pathway of XQLD in treatment of childhood CVA using...
Autores principales: | Ren, Yuzhe, Li, Xing, Zhang, Yuanjie, Yan, Zilong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617864/ https://www.ncbi.nlm.nih.gov/pubmed/37915641 http://dx.doi.org/10.1097/MS9.0000000000001326 |
Ejemplares similares
-
Exploring the mechanism of Xiaoqinglong decoction in the treatment of infantile asthma based on network pharmacology and molecular docking
por: Chen, Daman, et al.
Publicado: (2023) -
Traditional Chinese medicine formula Xiaoqinglong decoction for cough caused by COVID-19: A protocol for a systematic review and meta-analysis
por: Ren, Xiaodan, et al.
Publicado: (2020) -
Xiaoqinglong Decoction Attenuates Chronic Obstructive Pulmonary Disease in Rats via Inhibition of Autophagy
por: Wang, Huanan, et al.
Publicado: (2018) -
Xiaoqinglong Decoction Enhances Autophagy to Antagonist Airway Inflammation Induced by Cold in Asthmatic Rats
por: Wang, Bin, et al.
Publicado: (2022) -
Xiaoqinglong Decoction Protects the Lungs of AECOPD Mice through the AMPK/mTOR Signaling Pathway
por: Huang, Qingsong, et al.
Publicado: (2020)